Candel Therapeutics is set to report updated overall survival data for CAN-2409 in pancreatic ductal adenocarcinoma and non-small cell lung cancer in Q1 2025.
Candel Therapeutics' CAN-2409, combined with radiation therapy, significantly improved disease-free survival in localized prostate cancer patients in a Phase III trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.